Assisting a biopharmaceutical company before court

An Italian bio-pharmaceutical contract development and manufacturing company  has purchased two years ago certain intangible assets from its former foreign parent company, multinational group.  Price paid for such intangibles has proven to be much higher than expected returns would justify. A significant impairment loss had to be recorded only a few months after purchase was completed. The Italian company’s new management and ownership has instructed Salvidio & Partners to investigate about how price was determined and if the acquired intangibles were valued correctly as of purchase date. The case has been brought before court.